The market growth is driven by an increasing pharmaceutical industry's increasing focus on rare diseases and orphan drugs have spurred demand for specialized therapeutic approaches, including peptides and oligonucleotides. These molecules often play a crucial role in addressing the underlying genetic causes of rare diseases. As more research and development efforts are directed toward orphan drugs, CDMOs specializing in peptide and oligonucleotide manufacturing may see heightened demand for their services. Leading Companies focusing on Expanded Applications in Gene Therapy, Integration of Artificial Intelligence and Automation, Customization, Personalized Medicine Solutions, and others to boost market shares in the industry.
Peptides and Oligonucleotides are increasingly becoming important as Active Pharmaceutical Ingredients and playing a vital role in drug development. With increasing orphan disease niche indications, the demand for peptide and oligonucleotides is increasing rapidly. Accordingly, CDMO (contract development and manufacturing organizations) companies across the world are investing in aggressive marketing to capture the increasing market demand. In particular, innovation and technology, operational excellence, sustainability, customer centricity and service are widely marketed by CDMO companies.
A growing interest in peptides and oligonucleotides is widely observed. Research articles in PubMed feature over 400,000 peptide studies and over 180,000 oligonucleotides studies. In terms of pipeline, around 2500 peptides and oligonucleotides are in pharmaceutical pipeline. Around 70% of these are in preclinical stage and around 100 peptides and oligonucleotides are launched/commercially available.
The escalating utilization of peptides and oligonucleotides in therapeutic applications marks a pivotal shift in the landscape of medical treatments, particularly in addressing complex ailments like cancer, metabolic disorders, and genetic conditions. In cancer therapeutics, peptides have gained prominence due to their potential as targeted therapies.
Peptide-based drugs can precisely target cancer cells, minimizing adverse effects on healthy tissues. Additionally, they exhibit versatility in combating various stages and types of cancer, offering a promising avenue for personalized treatments. Oligonucleotides, on the other hand, are rapidly emerging as a transformative tool in cancer therapy by modulating gene expression, inhibiting tumor growth, and sensitizing tumors to traditional treatments like chemotherapy, enhancing their efficacy.
The growing demand for personalized medicine supports the demand for peptides and oligonucleotides. Driven by novel drug discovery, genomic research advances, personalized medicine is expanding into non-oncological indications. Leading pharmaceutical companies are emphasizing on understanding individual patient variations in drug metabolism, response, and potential side effects, allowing for the customization of dosage regimens and therapeutic strategies. Advances in high-throughput genomic sequencing technologies, Liquid biopsies, Targeted Drug Development, Immunotherapy Advancements, pharmacogenomics including optimize drug selection, dosage, and treatment regimens, minimizing adverse reactions and improving therapeutic outcomes, big data analytics, and Patient-Centric Approach drive the market outlook.
Advancements in technology are revolutionizing peptide and oligonucleotide manufacturing, opening doors to novel applications and significantly improving efficiency and scalability. Companies are opting for Implementation of advanced level of automation and digitalization for flexible, reliable, and scalable manufacturing processes.
Automated peptide synthesizers have become integral to peptide manufacturing. further, solid-phase peptide synthesis, continuous flow chemistry, modern purification techniques, such as high-performance liquid chromatography (HPLC) and preparative chromatography, advanced analytical tools, cell-free systems, advances in the synthesis of RNA and DNA, and others support the market outlook. In addition, advancements in oligonucleotide drug delivery systems also encourage the demand for large-scale peptide and oligonucleotide production.
Peptides have long been a therapeutic niche product but are becoming increasingly important in medicine as active ingredients. Peptides provide bioactivity that can mimic that of proteins, whereas oligonucleotides like DNA can be used as scaffolds to immobilize other molecules with nanoscale precision. Peptides can be used to improve the potency of therapeutic oligonucleotides by conferring tissue and attaching cell-targeting, cell-penetrating or antiviral and antibacterial properties to them. Three prominent areas where peptides are gaining strong demand include obesity, diabetes, and cancer treatments.
In addition, peptides are also in demand for cardiovascular and neurodegenerative diseases, renal failure, vaccines, antibiotics, and in drugs for rare diseases. The demand for peptide therapeutics has been increasing due to their specificity, effectiveness, and lower toxicity compared to traditional drugs. Peptide CDMOs play a pivotal role in helping pharmaceutical companies bring peptide-based drugs to market faster and more efficiently.
Traditional pharmaceutical companies primarily focus on small molecule drug development. Pharmaceutical CDMOs play a vital role in providing services related to chemical synthesis, formulation, and manufacturing of these small molecule drugs. Further, pharmaceutical companies involved in small molecule drug development also are exploring the use of oligonucleotides for specific applications, such as gene modulation. Further, pharmaceutical companies involved in the production of generic versions of peptide drugs and oligonucleotides also remain major consumers for CDMO Companies.
The US is the largest market for peptide and Oligonucleotide contract development and manufacturing, driven by the presence of large scale companies such as PolyPeptide Group, STA Pharmaceutical Co. Ltd., Bachem, Lonza, CMC Biopharma, and others. These companies are continuously investing in expanding their manufacturing lines and provide regulatory support for approval and marketing applications. The US remains the primary hub for pharmaceutical development outsourcing. Potential advantages of high quality, logistics, regulations, and IP rights make the market attractive for large companies. Amidst increasing number of complex and high potency compounds, CDMO companies stand out through advanced technologies and specialized expertise.
The growing emphasis on biologics, including peptides and oligonucleotides, in the pharmaceutical industry is creating opportunities for CDMOs. CDMO companies are investing in developing and manufacturing APIs for wide range of therapies that range from the treatment of wide-spread metabolic diseases like diabetes or obesity to cancer and cardiovascular or neurological disorders. In addition, ongoing research and development activities in the fields of oncology, rare diseases, and genetic disorders are driving the demand for specialized CDMO services. Further, the ability to navigate and adhere to the evolving regulatory landscape in the U.S., including FDA requirements presents robust advantages for domestic CDMOs.
The industry is fragmented in nature and is characterized by the presence of both capital-intensive global players and medium-scale local companies. Leading companies in the industry include- PolyPeptide Group, WuXi STA(Shanghai) Co.,Ltd (STA Pharmaceutical Co. Ltd.), Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, Sylentis, S.A., and others.
|
Stage |
Key Activities |
Key Companies |
Value Addition |
|
Discovery & Early Development |
Peptide/oligonucleotide synthesis, initial testing |
Eurofins Discovery, Bachem, GenScript |
Accelerates early research, reduces costs |
|
Process Development & Optimization |
Scale-up, process improvement |
CordenPharma, Polypeptide Group, WuXi AppTec |
Streamlines production, cost-effective scaling |
|
GMP Manufacturing |
Large-scale, compliant production |
Lonza, Bachem, Samsung Biologics, AGC Biologics |
Ensures regulatory compliance, consistent quality |
|
Quality Control & Analytical Testing |
Purity, potency, stability testing |
Almac Group, Charles River, SGS Life Sciences |
Guarantees safety, efficacy, and regulatory compliance |
|
Regulatory Support & Documentation |
Filing, compliance, documentation |
Parexel, Pharmaron, Syneos Health |
Reduces time to approval, ensures regulatory alignment |
|
Packaging & Distribution |
Secure packaging, logistics |
Sharp Packaging, PCI Pharma, Catalent |
Maintains product stability, compliant global distribution |
|
Clinical Trials & CRO Services |
Trial management, data analysis |
Covance, ICON plc, PPD (Thermo Fisher) |
Supports clinical testing, accelerates market entry |
|
Parameter |
Details |
|
Market Size (2024) |
$2.98 Billion |
|
Market Size (2032) |
$7.91 Billion |
|
Market Growth Rate |
12.95% |
|
Largest Segment- Types |
Peptides (64.3% Market Share) |
|
Largest Growing Segment- Applications |
Pharmaceutical Companies ($97.5 Million Revenue) |
|
Potential Market |
United States ($932.7 Million Sales) |
|
Segments |
Types, Sales Channels, Applications |
|
Study Period |
2018- 2023 and 2024-2032 |
|
Units |
Revenue (USD) |
|
Qualitative Analysis |
Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking |
|
Companies |
PolyPeptide Group, WuXi STA(Shanghai) Co.,Ltd (STA Pharmaceutical Co. Ltd.), Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, Sylentis, S.A. |
|
Countries |
US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa |
Type
Service
Applications
Countries Analyzed
Peptide and Oligonucleotide CDMO Companies Profiled in the Study
*- List Not Exhaustive
About USD Analytics
Table of Contents
1. Executive Summary
What’s New in 2024?
Top 10 Takeaways from the Industry
Potential Opportunities for Industry Stakeholders
Strategic Imperatives
Company Market Positioning
Industry Benchmarking Matrix
2. Research Scope and Methodology
Market Definition
Market Segments
Companies Profiled
Research Methodology
Data Sources
Conversion Rates for USD
Abbreviations
3. Strategic Landscape: Key Insights and Implications
Spotlight: Key Strategies Opted by Business Leaders
Competitive Landscape
SWOT Analysis
Porter’s Five Force Analysis
Macro-Environmental Analysis
4. Growth Opportunity Analysis
Trends at a Glance
Market Dynamics
Key Industry Stakeholders
Regulatory Landscape
5. Market Size Outlook to 2032
Global Peptide and Oligonucleotide CDMO Market Size Forecast, USD Million, 2018- 2032
Scenario Analysis
Pricing Analysis and Outlook
6. Historical Peptide and Oligonucleotide CDMO Market Size by Segments, 2018- 2023
Key Statistics, 2024
Peptide and Oligonucleotide CDMO Market Size Outlook by Type, USD Million, 2018-2023
Growth Comparison (y-o-y) across Peptide and Oligonucleotide CDMO Types, 2018-2023
Peptide and Oligonucleotide CDMO Market Size Outlook by Application, USD Million, 2018-2023
Growth Comparison (y-o-y) across Peptide and Oligonucleotide CDMO Applications, 2018-2023
7. Peptide and Oligonucleotide CDMO Market Size Outlook by Segments, 2024- 2032
Peptide and Oligonucleotide CDMO Market Size Outlook by Type, USD Million, 2024-2032
Growth Comparison (y-o-y) across Peptide and Oligonucleotide CDMO Types, 2024-2032
Peptide and Oligonucleotide CDMO Market Size Outlook by Service, USD Million, 2024-2032
Growth Comparison (y-o-y) across Peptide and Oligonucleotide CDMO Services, 2024-2032
Peptide and Oligonucleotide CDMO Market Size Outlook by Application, USD Million, 2024-2032
Growth Comparison (y-o-y) across Peptide and Oligonucleotide CDMO Applications, 2024-2032
8. Peptide and Oligonucleotide CDMO Market Size Outlook by Region
North America
Europe
Asia Pacific
South America
Middle East and Africa
9. United States Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
United States Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
United States Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
United States Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
10. Canada Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Canada Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Canada Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Canada Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
11. Mexico Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Mexico Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Mexico Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Mexico Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
12. Germany Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Germany Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Germany Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Germany Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
13. France Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
France Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
France Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
France Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
14. United Kingdom Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
United Kingdom Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
United Kingdom Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
United Kingdom Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
15. Spain Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Spain Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Spain Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Spain Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
16. Italy Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Italy Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Italy Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Italy Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
17. Benelux Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Benelux Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Benelux Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Benelux Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
18. Nordic Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Nordic Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Nordic Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Nordic Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
19. Rest of Europe Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Rest of Europe Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Rest of Europe Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Rest of Europe Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
20. China Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
China Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
China Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
China Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
21. India Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
India Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
India Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
India Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
22. Japan Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Japan Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Japan Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Japan Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
23. South Korea Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
South Korea Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
South Korea Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
South Korea Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
24. Australia Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Australia Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Australia Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Australia Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
25. South East Asia Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
South East Asia Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
South East Asia Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
South East Asia Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
26. Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Rest of Asia Pacific Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
27. Brazil Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Brazil Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Brazil Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Brazil Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
28. Argentina Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Argentina Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Argentina Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Argentina Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
29. Rest of South America Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Rest of South America Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Rest of South America Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Rest of South America Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
30. United Arab Emirates Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
United Arab Emirates Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
United Arab Emirates Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
United Arab Emirates Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
31. Saudi Arabia Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Saudi Arabia Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Saudi Arabia Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Saudi Arabia Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
32. Rest of Middle East Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Rest of Middle East Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Rest of Middle East Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Rest of Middle East Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
33. South Africa Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
South Africa Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
South Africa Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
South Africa Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
34. Rest of Africa Peptide and Oligonucleotide CDMO Market Analysis and Outlook, 2021- 2032
Key Statistics
Rest of Africa Peptide and Oligonucleotide CDMO Market Size Outlook by Type, 2021- 2032
Rest of Africa Peptide and Oligonucleotide CDMO Market Size Outlook by Application, 2021- 2032
Rest of Africa Peptide and Oligonucleotide CDMO Market Size Outlook by End-User, 2021- 2032
35. Key Companies
Market Share Analysis
Company Benchmarking
SWOT Analysis
36. Recent Market Developments
Appendix
Looking Ahead
Research Methodology
Legal Disclaimer
Type
Service
Applications
Countries Analyzed
USD Analytics forecasts the global Peptide and Oligonucleotide CDMO (contract development and manufacturing organizations) market size to increase from $2.98 Billion in 2024 to $7.91 Billion in 2032, registering a CAGR of 12.95% during the forecast period
Peptides (64.3% Market Share), Pharmaceutical Companies ($97.5 Million Revenue)
PolyPeptide Group, WuXi STA(Shanghai) Co.,Ltd (STA Pharmaceutical Co. Ltd.), Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, Sylentis, S.A.
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume
United States ($932.7 Million Sales)